Urinary proteomic profiles distinguish between active and inactive lupus nephritis

Area of Science:

• Nephrology
• Immunology
• Biomarker Discovery

Background:

• Lupus nephritis (LN) treatment aims for remission with minimal side effects.
• Current diagnostic tests for renal inflammatory activity in LN are insufficient, with renal biopsy being invasive and impractical for frequent use.
• There is a critical need for non-invasive biomarkers to monitor LN activity and treatment response.

Purpose of the Study:

• To identify novel urinary protein biomarkers for improved diagnosis and monitoring of lupus nephritis (LN).
• To assess the utility of these biomarkers in distinguishing active from inactive LN.
• To explore their potential in predicting disease relapse and remission.

Main Methods:

• Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) was employed to analyze urine protein profiles.
• Discriminant function analysis identified key proteins differentiating active (n=26) from inactive (n=49) LN.
• Prospective analysis of serial urines from six biopsied patients using multiple regression (MR) scores.

Main Results:

• Specific proteins (masses 3340 and 3980) distinguished active from inactive LN with 92% sensitivity and 92% specificity.
• Prospective MR scores predicted relapse and remission earlier than conventional clinical markers.
• SELDI-TOF MS successfully identified potential biomarker profiles associated with LN activity.

Conclusions:

• SELDI-TOF MS has identified promising urinary protein biomarkers for monitoring lupus nephritis activity.
• These biomarkers could lead to specific assays for routine disease monitoring and personalized immunosuppressive therapy adjustments.
• The identified proteins may also represent novel therapeutic targets for glomerulonephritis.